Aerie Pharmaceuticals, Inc.
AERIUnited States
30 filed reports · 376 financial concepts
Latest figures
Group totals as stated in the company’s own filed reports, each with a link to its report. The change is against the same period a year earlier.
Latest fiscal year
Filed reports
30 reports · Jun 2015 to Sep 2022Each report counts once it has at least one extracted financial fact.
| Report type | Reports | Facts | Periods |
|---|---|---|---|
| Quarterly · 10-QSEC EDGAR | 23 | 2,877 | Jun 2015 to Sep 2022 |
| Annual · 10-KSEC EDGAR | 7 | 2,542 | Dec 2015 to Dec 2021 |
Documents
| Period | Type | Period end | Published | Facts | Source |
|---|---|---|---|---|---|
| FY2022 Q3 | 10-Q | 2022-09-30 | 2022-11-04 | 315 | Open |
| FY2022 Q2 | 10-Q | 2022-06-30 | 2022-08-05 | 145 | Open |
| FY2022 Q1 | 10-Q | 2022-03-31 | 2022-05-06 | 160 | Open |
| FY2021 | 10-K | 2021-12-31 | 2022-02-25 | 625 | Open |
| FY2021 Q3 | 10-Q | 2021-09-30 | 2021-11-05 | 136 | Open |
| FY2021 Q2 | 10-Q | 2021-06-30 | 2021-08-05 | 109 | Open |
| FY2021 Q1 | 10-Q | 2021-03-31 | 2021-05-06 | 124 | Open |
| FY2020 | 10-K | 2020-12-31 | 2021-02-26 | 352 | Open |
| FY2020 Q3 | 10-Q | 2020-09-30 | 2020-11-06 | 141 | Open |
| FY2020 Q2 | 10-Q | 2020-06-30 | 2020-08-07 | 108 | Open |
| FY2020 Q1 | 10-Q | 2020-03-31 | 2020-05-07 | 118 | Open |
| FY2019 | 10-K | 2019-12-31 | 2020-02-24 | 302 | Open |
Financial data
376 concepts · 5,419 factsEach concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.
Financial370 concepts · 5,342 facts · Oct 2013 to Sep 2022
- Allocated share based compensation expense44 · Dec 2013 to Sep 2022
- Cash and cash equivalents at carrying value44 · Dec 2013 to Sep 2022
- Income loss from continuing operations before income taxes extraordinary items noncontrolling interest44 · Dec 2013 to Sep 2022
- Income tax expense benefit44 · Dec 2013 to Sep 2022
- Net income loss44 · Dec 2013 to Sep 2022
- Operating income loss44 · Dec 2013 to Sep 2022
- Other comprehensive income unrealized holding gain loss on securities arising during period net of tax44 · Dec 2013 to Sep 2022
- Other nonoperating income expense44 · Dec 2013 to Sep 2022
- Research and development expense44 · Dec 2013 to Sep 2022
- Depreciation42 · Dec 2013 to Sep 2022
- Increase decrease in accounts payable and other operating liabilities42 · Dec 2013 to Sep 2022
- Increase decrease in prepaid deferred expense and other assets42 · Dec 2013 to Sep 2022
- Payments to acquire property plant and equipment42 · Dec 2013 to Sep 2022
- Share based compensation42 · Dec 2013 to Sep 2022
- Comprehensive income net of tax41 · Mar 2014 to Sep 2022
- Stockholders equity (US GAAP)41 · Dec 2013 to Sep 2022
- Common stock par or stated value per share40 · Oct 2013 to Sep 2022
- Common stock shares authorized40 · Oct 2013 to Sep 2022
- Preferred stock par or stated value per share40 · Oct 2013 to Sep 2022
- Preferred stock shares authorized40 · Oct 2013 to Sep 2022
- Accounts payable current39 · Dec 2014 to Sep 2022
- Accrued Research And Development Expense Current39 · Dec 2014 to Sep 2022
- Additional paid in capital39 · Dec 2014 to Sep 2022
- Assets39 · Dec 2014 to Sep 2022
Geography4 concepts · 48 facts · Dec 2013 to Mar 2022
- Lease Agreement, Area of Interior Floor Space27 · Mar 2019 to Mar 2022
- Income loss from continuing operations before income taxes extraordinary items noncontrolling interest16 · Dec 2013 to Dec 2018
- Number Of Financial Institutions In Which Cash Deposited4 · Dec 2015 to Dec 2016
- Revenue From Contract With Customer, Total Market Sales1 · Dec 2019
Product2 concepts · 29 facts · Dec 2016 to Dec 2021
- Revenue25 · Dec 2016 to Dec 2021
- Percentage of Dosage Designed to Reduce Elevated Intraocular Pressure4 · Dec 2017 to Mar 2018
Segments
77 factsFigures broken down by business line, region, product or another axis the company reports on.
Statement geographicalsrt:StatementGeographicalAxis7 members · 34 facts
- California8 · Mar 2019 to Mar 2022
- North Carolina8 · Mar 2019 to Mar 2022
- New Jersey7 · Mar 2019 to Mar 2022
- Ireland4 · Jun 2019 to Mar 2022
- Other3 · Dec 2016 to Dec 2018
- United States3 · Dec 2016 to Dec 2018
- Europe1 · Dec 2019
Product or servicesrt:ProductOrServiceAxis2 members · 25 facts
- Product revenues, net22 · Dec 2016 to Dec 2021
- Licensing revenues3 · Dec 2019 to Dec 2021
Statement geographicalus-gaap:StatementGeographicalAxis3 members · 14 facts
- United States7 · Dec 2013 to Dec 2017
- Other5 · Dec 2013 to Dec 2017
- Europe2 · Dec 2015 to Dec 2016
Product or serviceus-gaap:ProductOrServiceAxis2 members · 4 facts
- Latanoprost2 · Dec 2017 to Mar 2018
- Rhopressa2 · Dec 2017 to Mar 2018
Text from filings
Management commentary and risk factors, extracted from SEC filings only.
No commentary or risk-factor text for this company.
Earnings calls
Transcripts with management claims and analyst questions, one per fiscal period.
No earnings-call transcripts for this company.
Executive media
Podcasts, interviews and conference appearances by the company's executives, with their claims.
No media appearances for this company.
Ask about this company in your AI model
Connect FactIQ to Claude, ChatGPT or another AI model (how to install), then paste this prompt.
Use FactIQ to get the revenue, net income and operating income of Aerie Pharmaceuticals, Inc. (AERI) from its filed reports, for the last five fiscal years and the latest quarter or half year. Link each figure to its filing, and chart the trend.
Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Nov 19, 2026) and refreshed every few hours.